Erasca (ERAS) vs Rhythm Pharmaceuticals (RYTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Erasca (ERAS) has outperformed Rhythm Pharmaceuticals (RYTM) over the past year, gaining 536.2% versus a loss of 10.6%. Over five years, RYTM leads with a +692.6% price change compared with -13.1% for ERAS. Rhythm Pharmaceuticals is the larger company by market cap ($6.17 billion vs $5.41 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ERAS | RYTM |
|---|---|---|
| Share price | $15.46 | $89.64 |
| Market cap | $5.41B | $6.17B |
| 1-day change | +9.49% | +1.35% |
| YTD return | +315.59% | -16.26% |
| 1-year return | +536.21% | -10.57% |
| 5-year return | -13.15% | +692.57% |
| EPS (TTM) | $-0.95 | $-3.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $189.76M |
| Revenue growth (YoY) | — | +45.83% |
| Net income (latest FY) | $-124.55M | $-196.54M |
| Gross margin | — | 89.73% |
| Operating margin | — | -101.19% |
| Net margin | — | -103.57% |
| 52-week high | $24.28 | $122.20 |
| 52-week low | $2.11 | $74.50 |
| Distance from 52-week high | -36.33% | -26.64% |
| Analyst consensus | none | none |
| Avg. price target upside | +55.95% | +54.61% |
| Average volume | 4.37M | 649.06K |
| Shares outstanding | 349.76M | 68.85M |
| Employees | 103 | 414 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed RYTM by 546.8 percentage points over the past year.
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
ERAS vs RYTM FAQ
Which is bigger, Erasca or Rhythm Pharmaceuticals?
Rhythm Pharmaceuticals (RYTM) is larger, with a market capitalization of $6.17B compared with $5.41B for Erasca (ERAS).
Which stock has performed better over the past year, ERAS or RYTM?
ERAS returned +536.21% over the past 12 months, compared with -10.57% for RYTM (price return, excluding dividends). Past performance does not predict future results.
Are Erasca and Rhythm Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.